Mitotane (o p’-DDD) an mouth adrenolytic agent for treatment of advanced
Mitotane (o p’-DDD) an mouth adrenolytic agent for treatment of advanced adrenocortical carcinoma (ACC) is reported to inhibit cortisol biosynthesis and enhance creation from exogenous cortisol of urinary 6β-hydroxycortisol and unidentified polar unconjugated metabolites. in untreated controls and 52 35 (imply range) in the mitotane plus hydrocortisone group. Ratios of 5α-/5β- and 20β-/20α-metabolites of administered … [Read more…]